phkineticaФармакокинетика и ФармакодинамикаPharmacokinetics and Pharmacodynamics2587-78362686-8830ООО «Издательство ОКИ»phkinetica-221Research ArticleФАРМАКОГЕНЕТИКАPHARMACOGENETICSГенетический полиморфизм и фармакокинетика лекарственных средствМирошниченкоИ. И.clinvest@mail.ruПтицинаС. Н.clinvest@mail.ruВНЦБАВ, Купавна, Московская областьRussian Federation20051103200502Клиническая фармакокинетика3539Copyright © Мирошниченко И.И., Птицина С.Н., 20052005Мирошниченко И.И., Птицина С.Н.Мирошниченко И.И., Птицина С.Н.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacokinetica.ru/jour/article/view/221

Взаимосвязь фармакологии и генетики носит двусторонний характер. С одной стороны, в рамках медицинской генетики изучается влияние лекарственных веществ на генетический аппарат. В настоящий момент необходимым этапом при создании новых лекарственных средств является изучение их мутагенности, что значительно повышает безопасность применения лекарств, исключая на доклиническом этапе вероятность нежелательных отдаленных последствий индуцированных мутаций.

генетический полиморфизмфармакокинетикаReferencesЕвгеньев М. И., Гармонов С. Ю., Погорельцев В. И. и др. Определение фенотипа ацетилирования для терапевтического мониторинга лекарственных средств. Клин лаб диагностика 1996; 5: 24-27.Евгеньев М. И., Гармонов С. Ю., Погорельцев В. И. и др. Определение фенотипа ацетилирования для терапевтического мониторинга лекарственных средств. Клин лаб диагностика 1996; 5: 24-27.Середенин С. Б., Вальдман Е. А. Фармакология и генетика. Новые перспективы и возможности. Вестник РГМУ 2003; 4: 30: 75-77.Середенин С. Б., Вальдман Е. А. Фармакология и генетика. Новые перспективы и возможности. Вестник РГМУ 2003; 4: 30: 75-77.Brosen K., Gram L. F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36: 537—547.Brosen K., Gram L. F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36: 537—547.Buck M. L. The cytochrome P450 enzyme system and its effect on drug metabolism. Pediatr Pharmacother 1997; 3: 5: 211-216.Buck M. L. The cytochrome P450 enzyme system and its effect on drug metabolism. Pediatr Pharmacother 1997; 3: 5: 211-216.Dahl M. L. Cytochrome P450 phenotyping in patients receiving antipsychotics. Useful aid to prescribing? Clin Pharmacokin 2002; 41: 453-470.Dahl M. L. Cytochrome P450 phenotyping in patients receiving antipsychotics. Useful aid to prescribing? Clin Pharmacokin 2002; 41: 453-470.Flexner C. W. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring. Top HIV Med 2003; 11: 2: 40-44.Flexner C. W. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring. Top HIV Med 2003; 11: 2: 40-44.Gunaratna C. Drug metabolism and pharmacokinetics in drug discovery: a primer for bioanalytical chemists, part I. Current Separations BAS 2000; 19: 1: 17-23.Gunaratna C. Drug metabolism and pharmacokinetics in drug discovery: a primer for bioanalytical chemists, part I. Current Separations BAS 2000; 19: 1: 17-23.Hashimoto Y, Nakayama T. Futamura A. et al. Relationship between genetic polymorphisms of alcohol-metabolizing enzymes and changes in risk factors for coronary heart disease associated with alcohol consumption. Clin Chem 2002; 48: 7: 1043-1048.Hashimoto Y, Nakayama T. Futamura A. et al. Relationship between genetic polymorphisms of alcohol-metabolizing enzymes and changes in risk factors for coronary heart disease associated with alcohol consumption. Clin Chem 2002; 48: 7: 1043-1048.Harris C. C. Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis 1989; 10: 1563—1566.Harris C. C. Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis 1989; 10: 1563—1566.Ji L., Pan S., Marti-Jaun J. et al. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 2002;48: 7: 983-988.Ji L., Pan S., Marti-Jaun J. et al. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 2002;48: 7: 983-988.Kawajiri K., Nakachi K., Imai K. et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990; 263:131—133.Kawajiri K., Nakachi K., Imai K. et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990; 263:131—133.Kidd R. S., Straughn A. B., Meyer M. C. et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9: 1: 71-80.Kidd R. S., Straughn A. B., Meyer M. C. et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9: 1: 71-80.Kurata Y., Ieiri I., Kimura M. et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72:209-219.Kurata Y., Ieiri I., Kimura M. et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72:209-219.Kwan K. C. Oral bioavailability and first-pass effects. Drug Metab Dispos 1997; 25: 12: 1329-1336.Kwan K. C. Oral bioavailability and first-pass effects. Drug Metab Dispos 1997; 25: 12: 1329-1336.Linder M. W., Prough R. A., Valdes R. Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997; 43: 2: 254-266.Linder M. W., Prough R. A., Valdes R. Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997; 43: 2: 254-266.Linder M. W., Valdes R. Jr. Genetic mechanisms for variability in drug response and toxicity. J Anal Toxicol 2001; 25: 5: 405-413.Linder M. W., Valdes R. Jr. Genetic mechanisms for variability in drug response and toxicity. J Anal Toxicol 2001; 25: 5: 405-413.Maiorana A., Roach R. B. Jr. Heterozygous pseudocholinesterase deficiency: a case report and review of the literature. J Oral Maxillofac Surg. 2003; 61: 7: 845-847.Maiorana A., Roach R. B. Jr. Heterozygous pseudocholinesterase deficiency: a case report and review of the literature. J Oral Maxillofac Surg. 2003; 61: 7: 845-847.Meyer J. M., Rodvold K. A. Drug biotransformation by the cytochrome P-450 enzyme system. Infect Med 1996; 13: 6: 452, 459, 463-464, 523.Meyer J. M., Rodvold K. A. Drug biotransformation by the cytochrome P-450 enzyme system. Infect Med 1996; 13: 6: 452, 459, 463-464, 523.Nakachi K., Imai K., Hayashi S., Watanabe J. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1991; 51: 5177—5180.Nakachi K., Imai K., Hayashi S., Watanabe J. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1991; 51: 5177—5180.Rettie A. E., Wienkers L. C., Gonzalez F. J. et al. Impaired (S) -warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994: 4: 39—42.Rettie A. E., Wienkers L. C., Gonzalez F. J. et al. Impaired (S) -warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994: 4: 39—42.Rogers J. F., Nafziger A. N., Bertino J. S. Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113: 9: 746-750.Rogers J. F., Nafziger A. N., Bertino J. S. Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113: 9: 746-750.Weber W. W. Populations and genetic polymorphisms. Mol Diagn – 1999; 4: 4: 299-307.Weber W. W. Populations and genetic polymorphisms. Mol Diagn – 1999; 4: 4: 299-307.

The authors declare that there are no conflicts of interest present.